Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 401–500 of 2,656
The role of hypoxia-inducible factors 1 and 2 in the pathogenesis of diabetic kidney disease
Kleibert, M., Tkacz, K., Winiarska, K., Małyszko, J., & Cudnoch‐Jędrzejewska, A. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02152-x · Cited by 22
The 2024 APLAR Consensus on the Management of Lupus Nephritis
Mok, C. C., So, H., Hamijoyo, L., Kasitanon, N., Chen, D., Bae, S., Li, M. T., Navarra, S., Yap, D. Y. H., & Tanaka, Y. (2025) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.70021 · Cited by 24
Uchiyama, K., Kamano, D., Nagasaka, T., Hama, E. Y., Shirai, R., Sumura, R., Kusahana, E., Yanai, A., Nakayama, T., Kimura, T., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.01.023 · Cited by 24
SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy
Viggiano, D., Joshi, R., Borriello, G., Cacciola, G., Gonnella, A., Gigliotti, A., Nigro, M., & Gigliotti, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041241 · Cited by 21
A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors
O’Hara, D. V., & Jardine, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16385 · Cited by 24
“…000 participant-years of follow-up in the large SGLT2 inhibitor trials, there was only a single event recorded of ketoacidosis in a participant without diabetes at baseline, 3 occurring in the Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease (EMPA-KIDNEY) trial 7 .”
InfluentialCVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 23
“Three kidney outcome trials have been completed with SGLT2is [43–45] and one with finerenone [46].”
Hacil, A., Antakly, Y., Lacour, A., David, J.-P., Khalifa, T., Piccoli, M., Clemencin, A., Assayag, P., Vidal, J., & Hanon, O. (2025) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag193.770 · Cited by 22
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 23
“The EMPA KIDNEY study [80] included 6609 patients with CKD, defined as an eGFR of 20 -< 45 mL/min/1.”
BackgroundMethodResultInfluentialde la Flor, J. C., Villa, D. E., Vega, L. L. C., Apaza, J., Valga, F., Zamora, R., Marschall, A., Terrones, M. C., Deira, J., & Rodeles, M. (2023) · Biomedicines · doi:10.3390/biomedicines11071908 · Cited by 28
“This trial demonstrated consistent benefits of empagliflozin treatment in reducing the risk of kidney disease progression or death from cardiovascular causes compared to the placebo, even in the population with lower eGFR [9].”
BackgroundThe Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
Matthews, J. R., Herat, L. Y., Schlaich, M. P., & Matthews, V. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814243 · Cited by 26
“2022 EMPAKIDNEY Empagliflozin Patients with CKD 6609 ↓ Progression of Kidney Disease ↓ Death from Cardiovascular Causes [60]”
SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review
Maxson, R., Starr, J. A., Sewell, J., & Lyas, C. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.10.014 · Cited by 27
Mottl, A. K., & Nicholas, S. B. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.09.003 · Cited by 31
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression
Holliday, M. W., Frost, L. A., & Navaneethan, S. D. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000976 · Cited by 22
(2024) · Editora Conhecimento Livre eBooks · doi:10.37423/2024.edcl940 · Cited by 33
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials
Wanner, C., Iliev, H., Duarte, N., Schueler, E., Soares, A. R., Thanam, V., & Pfarr, E. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02879-w · Cited by 28
Christodorescu, R., Geavlete, O. D., Ferrini, M., Kümler, T., Toutoutzas, K., Bayés‐Genís, A., Seferovic, P. M., Metra, M., Chioncel, O., Rosano, G. M. C., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3444 · Cited by 18
Garg, R., Sood, N., Bansal, O., & Hoskote, A. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09073-2 · Cited by 28
Zannad, F. M., McGuire, D. K., & Ortíz, A. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20050 · Cited by 22
Delrue, C., & Speeckaert, M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157606 · Cited by 23
Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., Vaduganathan, M., BRINKER, M. D., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1673 · Cited by 26
Kandel, R., Roy, P., & Singh, K. P. (2025) · Frontiers in Bioscience-Scholar · doi:10.31083/fbs38963 · Cited by 31
Management of heart failure in patients with kidney disease—updates from the 2021 ESC guidelines
Edwards, N. C., Price, A. M., Steeds, R. P., Ferro, C. J., & Townend, J. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad011 · Cited by 22
Ngoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 24
“empagliflozin in patients with CKD, which was independent of diabetes status.(11,27) Among nsMRAs, finerenone selectively inhibits mineralocorticoid receptors, which results in reductions in renal inflammation, fibrosis and vasoconstriction.”
BackgroundRecent advances in the treatment of patients with obesity and chronic kidney disease
Wahab, R. A., COHEN, R. V., & le Roux, C. W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2203517 · Cited by 25
Bell, D. S. H., McGill, J. B., & Jerkins, T. W. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15181 · Cited by 19
“73m(2), a sustained decrease in eGFR of ≥ 40% from baseline, or death from renal causes) or CV-related death following empagliflozin treatment compared with placebo.(64)”
BackgroundThe Role of Autophagy in Type 2 Diabetic Kidney Disease Management
Tseng, C.-H., Shah, K. M., Chiu, I., & Hsiao, L. (2023) · Cells · doi:10.3390/cells12232691 · Cited by 21
Oka, K., Masuda, T., Ohara, K., Miura, M., Morinari, M., Misawa, K., Miyazawa, Y., Akimoto, T., Shimada, K., & Nagata, D. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1287066 · Cited by 22
“…or without diabetes (DAPA-CKD and EMPA-KIDNEY trials), the SGLT2 inhibitors dapagliflozin and empagliflozin significantly decreased the combined risk of a sustained decline in the estimated glomerular filtration rate, end-stage renal disease, and death from renal or cardiovascular causes (10, 11).”
BackgroundYi, T. W., O’Hara, D. V., Smyth, B. J., Jardine, M., Levin, A., & Morton, R. L. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581231217857 · Cited by 22
Raikou, V. D. (2024) · World Journal of Nephrology · doi:10.5527/wjn.v13.i1.89637 · Cited by 23
Individualized Risk of CKD Progression among US Adults
Tio, M. C., Butler, J., Zhu, X., Obi, Y., Yen, T. E., Kalantar‐Zadeh, K., Streja, E., Dossabhoy, N. R., Hall, M. E., & Shafi, T. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000377 · Cited by 21
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14202 · Cited by 22
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00723-8 · Cited by 21
Sansone, N. M. S., Boschiero, M. N., & Marson, F. A. L. (2024) · Biomedicines · doi:10.3390/biomedicines12102206 · Cited by 20
Sodium-Glucose Cotransporter-2 Inhibitor in Diabetic and Nondiabetic Renal Transplant Recipients
Maigret, L., Baslé, L., Châtelet, V., Écotière, L., Perrin, P., Golbin, L., Bertrand, D., Anglicheau, D., Poulain, C., Garrouste, C., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.11.033 · Cited by 20
2023 Guideline for the management of hypertension in the elderly population in China
Hua, Q., Fan, L., Wang, Z., & Li, J. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.06.001 · Cited by 23
Siddiqi, T. J., Cherney, D. Z. I., Siddiqui, H. F., Jafar, T. H., Januzzi, J. L., Khan, M. S., Levin, A., Marx, N., Rangaswami, J., Testani, J. M., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000491 · Cited by 27
SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease
Júnior, P. A. B. M., Lass, A. D., Pilger, B. I., Fornazari, R., de Moraes, T. P., & Pinho, R. A. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2023-0187en · Cited by 33
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 21
Anemia Management in the Cardiorenal Patient: A Nephrological Perspective
Marqués, M., Portolés, J. M., Marcos, M. C., Gorriz, J. L., Núñez, J. E., & Cases, A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037363 · Cited by 23
Heart Failure in Older Patients: An Update
Montalto, M., D'Ignazio, F., Camilli, S., Francesco, S. D., Fedele, M., Landi, F., & Gallo, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061982 · Cited by 26
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 26
Metra, M., Tomasoni, D., Adamo, M., Amir, O., Anker, S. D., Bayés‐Genís, A., Böehm, M., Butler, J., Chioncel, O. D., Filippatos, G. S., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15408 · Cited by 28
Oprea, A. D., Mohamed, B. A., Hepner, D. L., Auron, M., Richman, D. C., Umpierrez, G. E., Edmonston, D. L., Ionescu, C., Kumar, M., & Sweitzer, B. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.02.031 · Cited by 27
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Chan, J. C. H., & Chan, M. C. Y. (2023) · Medicina · doi:10.3390/medicina59020388 · Cited by 28
Ma, C., Li, X., Li, W., Li, Y., Shui, F., & Zhu, P. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03586-1 · Cited by 22
Bapir, R., Bhatti, K. H., Eliwa, A., García‐Perdomo, H. A., Gherabi, N., Hennessey, D. B., Magri, V., Mourmouris, P., Ouattara, A., Perletti, G., et al. (2023) · Archivio Italiano di Urologia e Andrologia · doi:10.4081/aiua.2023.11509 · Cited by 25
Metabolic Approaches for the Treatment of Dilated Cardiomyopathy
Spoladore, R., Pinto, G., Daus, F., Pezzini, S., Kolios, D., & Fragasso, G. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10070287 · Cited by 17
“Of note, dapagliflozin and empagliflozin, in DAPA-CKD and EMPA-KIDNEY trials, respectively, reduced the risk of kidney failure in chronic kidney disease (CKD) patients with or without T2DM, independently of a history of HF [141,142].”
BackgroundRojas-Rivera, J. E., Bakkaloglu, S. A., Bolignano, D., Nistor, I., Sarafidis, P. A., Stoumpos, S., Cozzolino, M. G., & Ortíz, A. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad154 · Cited by 20
Raven, L. M., Muir, C. A., & Greenfield, J. R. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52067 · Cited by 18
Lipska, K. J., Huang, E. S., Liu, J. Y., Parker, M. M., Laiteerapong, N., Grant, R. W., Moffet, H. H., & Karter, A. J. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18565 · Cited by 21
Campos, M. A. J., Andújar, I., Keller, F., Mayer, G. J., Rossing, P. R., Staessen, J. A., Delles, C., Beige, J., Glorieux, G., Clark, A. L., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16091298 · Cited by 17
Chen, X., Li, X., Zhang, K., Lian, K., Zhang, W., Song, Y., Kan, C., Zhang, J., Han, F., Sun, X., et al. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02413-2 · Cited by 19
Ferrannini, E., Solini, A., Baldi, S., Scozzaro, T., Polidori, D., Natali, A., & Hansen, M. K. (2023) · Diabetes · doi:10.2337/db23-0448 · Cited by 19
Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
Chen, X., Wang, J., Lin, Y., Yao, K., Xie, Y., & Zhou, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236404 · Cited by 21
SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy
Oe, Y., Kim, Y. C., Sidorenko, V. S., Zhang, H., Kanoo, S., Lopez, N., Goodluck, H. A., Crespo‐Masip, M., & Vallon, V. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00228.2023 · Cited by 20
Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD
Nakatani, S., Morioka, F., Uedono, H., Tsuda, A., Mori, K., & Emoto, M. (2023) · CEN Case Reports · doi:10.1007/s13730-023-00840-4 · Cited by 18
“Recently, the presented results of the DAPA–CKD trial [10] and EMPA–Kidney trial [11] indicate kidney protective effects of such medications in CKD patients both with and without diabetes.”
Use of ACEi/ARBs, SGLT2 inhibitors and MRAs can help us reach the therapeutic ceiling in CKD
Sarafidis, P. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae014 · Cited by 24
Management of Patients With Kidney Disease Undergoing Bariatric Surgery
Kukla, A., Kudva, Y. C., Navrátil, P., Sahi, S. S., Benzo, R. P., Fipps, D. C., Erickson, A. E., Majorowicz, R. R., Clark, M. M., Schinstock, C. A., et al. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.11.008 · Cited by 18
Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds
Benedikt, M., Oulhaj, A., Rohrer, U., Manninger, M., Tripolt, N. J., Pferschy, P. N., Aziz, F., Wallner, M., Kolesnik, E., Gwechenberger, M., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400147 · Cited by 19
Jeon, J. Y., & Kim, D. J. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0317 · Cited by 26
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Ospina, N. S., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16147 · Cited by 20
Lin, Y., Wu, J., Lee, M.-C., Su, C.-Y., Toh, H. S., Chang, W., Chen, S.-Y., Kuo, F., Tang, H., & Liao, C. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae093 · Cited by 20
“16 With the emergence of more recent studies, 17 , 18 these conflicting results underscore the need for a systematic review and meta-analysis to consolidate the evidence and clarify the overall treat-ment effects.”
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 22
Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes
Bonnesen, K., Heide-Jørgensen, U., Christensen, D. H., Christiansen, C. F., Lash, T. L., Hennessy, S., Matthews, A. A., Pedersen, L., Thomsen, R. W., & Schmidt, M. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.7381 · Cited by 17
Nyström, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15696 · Cited by 21
“heart failure (HF) 27,28 and chronic kidney disease (CKD), 29,30 benefiting not only diabetic patients but also those without diabetes.”
Wang, J., Shi, H., Yang, Y. S., & Gong, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1505794 · Cited by 30
Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females
Doi, Y., Hamano, T., Yamaguchi, O., & Isaka, Y. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016320 · Cited by 21
Monnerat, S., Christ‐Crain, M., & Refardt, J. C. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01138-4 · Cited by 26
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 37
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
Next-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 28
A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
Sano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065983 · Cited by 18
“In phase III trials, SGLT2 inhibitors improved outcomes in diabetic and non-diabetic kidney diseases [12,18,19].”
BackgroundManaging Hyperkalemia in the Modern Era: A Case-Based Approach
Massicotte‐Azarniouch, D., Canney, M., Sood, M. M., & Hundemer, G. L. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.04.016 · Cited by 19
“The EMPAKIDNEY trial, which examined the use of empagliflozin in patients with proteinuric and nonproteinuric CKD, demonstrated a significant reduction in progression of kidney disease or death from cardiovascular causes, although this effect was not seen in the subgroup of patients with low-level or no proteinuria.(4…”
MethodNgoc, N. B., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15201 · Cited by 19
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01121-x · Cited by 25
Bakbak, E., Verma, S., Krishnaraj, A., Quan, A., Wang, C., Pan, Y., Puar, P., Mason, T., Verma, R., Terenzi, D. C., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00141.2023 · Cited by 19
Шамхалова, М. Ш., Vikulova, O. K., Zheleznyakova, A. V., Исаков, М. А., Shestakova, M. V., Dedov, I. I., & Mokrysheva, N. G. (2023) · Diabetes Mellitus · doi:10.14341/dm13090 · Cited by 24
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 18
“Following initial signals of kidney benefit from SGLT2 inhibitor CVOTs [49 –51 ], three dedicated kidney outcome trials have been conducted with canagliflozin, dapagliflozin, and empagliflozin, respectively ( Table 1 ) [52 –54 ].”
BackgroundResultTangri, N., Rastogi, A., Nan, C., Hong, L., Ozaki, A., Franzén, S., & Sofue, T. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02773-x · Cited by 22
Kidney health matters: a global imperative for public health
Torrá, R. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae083 · Cited by 20
Madonna, R., Biondi, F., Alberti, M., Ghelardoni, S., Mattii, L., & D’Alleva, A. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116650 · Cited by 19
Cardiorenal Syndromes and Their Role in Water and Sodium Homeostasis
Salajová, K. B., Malík, J., & Valeriánová, A. (2024) · Physiological Research · doi:10.33549/physiolres.935110 · Cited by 29
Asakura, M., Masuda, T., Oka, K., Ohara, K., Miura, M., Morinari, M., Misawa, K., Miyazawa, Y., Akimoto, T., Shimada, K., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14111194 · Cited by 19
Czupryniak, L., Mosenzon, O., Rychlík, I., Clodi, M., Ebrahimi, F., Janež, A., Kempler, P., Malecki, M. T., Moshkovich, E., Prázný, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15789 · Cited by 21
“80 25, 80 SCORED also included patients with and without albuminuria.”
Gregg, L. P., Richardson, P. A., Nambi, V., Petersen, L. A., Matheny, M. E., Virani, S. S., & Navaneethan, S. D. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000477 · Cited by 19
Sato, A., Rodríguez-Molina, D., Yoshikawa‐Ryan, K., Yamashita, S., Okami, S., Liu, F., Farjat, A. E., Oberprieler, N. G., Kovesdy, C. P., Kanasaki, K., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175107 · Cited by 18
Jhu, J., Fang, Y., Huang, C., Liou, H., Chen, M., & Tsai, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14361 · Cited by 19
“According to the fi ndings of the CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials, SGLT2i is effective in reducing the risks of progression to ESKD, renal or cardiovascular mortality, and decline in eGFR from baseline in patients with diabetic kidney disease 11,12,37 .”
Monnerat, S., Atila, C., Refardt, J. C., & Christ‐Crain, M. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad011 · Cited by 17
Hanouneh, M. A., Le, D., Jaar, B. G., Tamargo, C. L., & Cervantes, C. E. (2024) · Diagnostics · doi:10.3390/diagnostics14131357 · Cited by 17
Phillips, P. C. A., Branco, M. S. L. A., Cliff, C. L., Ward, J. K., Squires, P. E., & Hills, C. E. (2024) · Diabetic Medicine · doi:10.1111/dme.15408 · Cited by 20
van Mil, D., Vart, P., Chertow, G. M., Gansevoort, R. T., Rossing, P. R., Toto, R. D., Correa-Rotter, R., Langkilde, A. M., Sjöström, C. D., Wheeler, D. C., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000550 · Cited by 20
Adamczak, M., Kurnatowska, I., Naumnik, B., Stompór, T. P., Tylicki, L., & Krajewska, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312941 · Cited by 21
Hunsuwan, S., Boongird, S., Ingsathit, A., Ponthongmak, W., Unwanatham, N., McKay, G. J., Attia, J., & Thakkinstian, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-86172-y · Cited by 16
Hanaoka, H., Aoki, T., Kosaka, T., Yoshinaga, S., Shibata, A., Sakai, R., Kurasawa, T., & Amano, K. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2460267 · Cited by 24
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 24
SGLT2 inhibitors in CKD: are they really effective in all patients?
Romagnani, P. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf051 · Cited by 23
Chuang, M., Wang, H., Kan, W., Chien, C.-C., Jiang, M., Huang, Y., Wu, V., & Chen, J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf064 · Cited by 19
“…like Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [5 ], Dapagliflozin in Patients with Chronic Kidney Disease [6 ] and Empagliflozin in patients with chronic kidney disease [7 ] highlighting their utility in managing CKD among patients with or without diabetes mellitus [8 ].”
Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys
Zbrzeźniak, J., Winiarska, A., Perkowska‐Ptasińska, A., & Stompór, T. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136247 · Cited by 23
SGLT2 inhibitors and acute kidney injury
Nakao, Y., Mori, M., Mori, Y., & Bonventre, J. V. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf132 · Cited by 21
Kaul, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.036 · Cited by 19
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.